FDA Warns 30 Telehealth Companies and Targets Compounded GLP-1 Drugs in Major Crackdown

Why Is the FDA Cracking Down on Compounded GLP-1 Medications?

The explosive demand for GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created a parallel market of compounded versions that bypass FDA approval requirements. Compounding pharmacies, which traditionally prepare customized medications for individual patients with specific needs, have increasingly produced large quantities of GLP-1 lookalikes marketed directly to consumers through telehealth platforms. The FDA's 30 warning letters target companies making claims that their compounded products are equivalent to, or interchangeable with, FDA-approved brands — assertions the agency says are false and misleading.

The safety concerns are not theoretical. Compounded medications do not undergo the rigorous testing for potency, sterility, stability, and purity that FDA-approved drugs require. Reports of adverse events linked to compounded GLP-1 products have increased, including injection site infections, dosing inconsistencies, and contamination. The FDA emphasized that compounded semaglutide salt forms — particularly semaglutide sodium and semaglutide acetate — are not the same as the FDA-approved semaglutide base and have not been evaluated for safety or efficacy in clinical trials.

What Steps Is the FDA Taking to Restrict Compounded GLP-1 Drugs?

In a parallel announcement, the FDA declared its intent to take decisive steps to restrict the active pharmaceutical ingredients (APIs) used to manufacture compounded GLP-1 medications. Under the Federal Food, Drug, and Cosmetic Act, compounding is permitted under specific conditions — typically when an FDA-approved drug is in shortage or when a patient has a documented medical need for a customized formulation. With the GLP-1 drug shortage having eased as manufacturers ramped up production, the legal basis for large-scale compounding has weakened considerably.

The FDA's planned restrictions would target both 503A pharmacies (traditional compounding pharmacies filling individual prescriptions) and 503B outsourcing facilities (which produce compounded drugs in larger batches without individual prescriptions). By restricting access to semaglutide and tirzepatide APIs, the agency aims to eliminate the supply chain that enables mass production of non-approved GLP-1 formulations. Industry analysts note this could affect hundreds of compounding operations and displace millions of patients currently using compounded versions, raising questions about how those patients will transition to FDA-approved alternatives given ongoing cost and access barriers.

What Should Patients Using Compounded GLP-1 Drugs Do Now?

The FDA's enforcement actions do not take effect immediately, but patients currently using compounded semaglutide or tirzepatide should begin planning a transition to FDA-approved alternatives with their healthcare provider. Abruptly discontinuing GLP-1 therapy can lead to rapid weight regain and, for patients with type 2 diabetes, loss of glycemic control. Healthcare providers can help patients navigate insurance coverage, manufacturer savings programs, and authorized pharmacy channels for obtaining FDA-approved formulations.

Consumer advocacy groups have raised concerns that the crackdown may disproportionately affect patients who turned to compounded versions because they could not afford the list prices of branded GLP-1 drugs, which can exceed $1,000 per month without insurance. The FDA acknowledged these access challenges but maintained that patient safety must take priority over cost considerations, noting that the agency cannot ensure the quality or consistency of non-approved compounded products. Meanwhile, manufacturer patient assistance programs and the recent approval of higher-dose Wegovy (semaglutide 7.2 mg) may provide additional options for patients seeking affordable, FDA-approved treatments.